Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MARLINA phase IIIb trial of linagliptin in type 2 diabetes with albuminuria
2012-002603-17Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Linagliptin plus background ACEi or ARB with Placebo plus background ACEi or ARB (2 arms). Primary endpoint: Change from baseline in HbA1c. Started Oct 2012; status: completed.
02
Drugs
linagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2012-002603-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002603-17.